Table 1 Essential clinicopathological and molecular characteristics of the three breast cancer groups investigated.
LS-associated breast cancers | LS-associated breast cancers | ||
|---|---|---|---|
Carriers | Non-carriers | Sporadic breast cancer c | |
No. of tumors | 23 | 18 | 49 |
ductal | 17 | 14 | 30 |
ductal in situ | 2 | 1 | - |
lobular | 3 | - | 19 |
other | 1 | 2 | - |
no histological data | - | 1 | - |
Size (= 20 mm) | 7/19 (37%) | 9/14 (64%) | 30/49 (61%) |
G1 | 2/19 (11%) | 4/12 (33%) | 12/46 (26%) |
G2 | 10/19 (53%) | 5/12 (42%) | 29/46 (63%) |
G3 | 7/19 (37%) | 3/12 (25%) | 5/46 (11%) |
Lymph node metastases | 6/16 (38%) | 7/10 (70%) | 28/47 (60%) |
Receptor status: | |||
ER-positivity | 20/22 (91%) | 6/7 (86%) | 49/49 (100%) |
PR-positivity | 15/22 (68%) | 5/7 (71%) | 41/46 (89%) |
HER2-positivity | 3/20 (15%) | 1/6 (17%) | 0/49 (0%) |
Average age at diagnosis (years) | 56 | 54 | 61 |
MSI | 8/23 (35%) | 0/18 (0%) | N/A |
MMR protein reduced or lost | 13/20 (65%) a | 0/14 (0%) b | 0/49 (0%) b |
Average number of TSGs methylated out of 24 per tumor | 2.3 | 2.0 | 2.4 |